Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Atrasentan hydrochloride by Novartis for Focal Segmental Glomerulosclerosis (FSGS): Likelihood of Approval
Atrasentan hydrochloride is under clinical development by Novartis and currently in Phase II for Focal Segmental Glomerulosclerosis (FSGS). According to...
Atrasentan hydrochloride by Novartis for Kidney Disease (Nephropathy): Likelihood of Approval
Atrasentan hydrochloride is under clinical development by Novartis and currently in Phase II for Kidney Disease (Nephropathy). According to GlobalData,...
Atrasentan hydrochloride by Novartis for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Atrasentan hydrochloride is under clinical development by Novartis and currently in Pre-Registration for IgA Nephropathy (Berger's Disease). According to GlobalData,...
Atrasentan hydrochloride by Novartis for Diabetic Nephropathy: Likelihood of Approval
Atrasentan hydrochloride is under clinical development by Novartis and currently in Phase II for Diabetic Nephropathy. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Novartis's Atrasentan hydrochloride?
Atrasentan hydrochloride is a small molecule commercialized by Novartis, with a leading Pre-Registration program in IgA Nephropathy (Berger's Disease). According...
Risk adjusted net present value: What is the current valuation of Novartis's Atrasentan hydrochloride?
Atrasentan hydrochloride is a small molecule commercialized by Novartis, with a leading Phase III program in IgA Nephropathy (Berger's Disease)....